Market Overview

According to fortune business insights, the global cancer biomarkers market size was valued at USD 42.87 billion in 2025. The market is projected to grow from USD 48.2 billion in 2026 to USD 83.61 billion by 2034, exhibiting a CAGR of 7.13% during the forecast period. North America dominated the cancer biomarkers market with a market share of 35.94% in 2025.

The analysis shows that the rising prevalence of cancer globally is increasing the demand for early disease diagnosis, subsequently propelling market growth. The expanding use of biomarkers in drug discovery, development, and the shift toward personalized medicine are also key factors. This trend indicates a strong demand for cancer biomarkers worldwide.

Major Players Profiled in the Market Report:

• F. Hoffmann-La Roche Ltd.
• Abbott
• Thermo Fisher Scientific
• Bio-Rad Laboratories, Inc.
• CENTOGENE N.V.
• Axon Medchem
• Sino Biological Inc.
• R&D System
• BioVision Inc.
• Myriad RBM

Segments

Rising Prevalence to Propel Breast Cancer Segment Growth

Based on cancer type, the market is segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, and others. The breast cancer segment holds the largest market share, driven by the increasing prevalence of the disease and a rise in awareness about early diagnosis. This has led to a large patient pool undergoing diagnostic tests, supported by rising research activities focused on new biomarkers for breast cancer detection.

High Prevalence of Breast Cancer to Drive HER-2 Segment Expansion

By biomarker type, the market is categorized into PSA, HER-2, EGFR, KRAS, and others. The HER-2 segment is leading the market, driven by the rising prevalence of breast cancer and increasing awareness about disease diagnosis in both developed and developing countries. The introduction of new HER-2-based tests, including liquid biopsy, is further propelling global demand.

New Product Introductions to Dominate the Diagnostics & Research Laboratories Segment